SCHEMBL10129609

SCHEMBL10129609

CCOC(=O)c1ccc(Cl)nc1N[C@H]1CCCC[C@@H]1N

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FER P16591 3/20 0.45
SYK P43405 13/20 0.43
MAPK1 P28482 4/20 0.43
MAPK3 P27361 3/20 0.43
KCNH2 Q12809 3/20 0.43
AURKB Q96GD4 3/20 0.43
JAK2 O60674 1/20 0.42
ROCK2 O75116 1/20 0.42
MAP4K4 O95819 1/20 0.42
HCK P08631 1/20 0.42
ROS1 P08922 1/20 0.42
PIM1 P11309 1/20 0.42
PRKACA P17612 1/20 0.42
MARK3 P27448 1/20 0.42
LTK P29376 1/20 0.42
FLT3 P36888 1/20 0.42
CSNK1A1 P48729 1/20 0.42
CLK2 P49760 1/20 0.42
MAPK10 P53779 1/20 0.42
MAP2K1 Q02750 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10129614 0.84 NR2F2 (0.40) SYKMAPK1DYRK1ANR2F2NPSR1
SCHEMBL496019 0.84 NR2F2 (0.53) MAPK1NR2F2NPSR1KDM4EMAPT
SCHEMBL20891573 0.77 KDM4E (0.48) ALKKDM4EMAPTALOX15MEN1
SCHEMBL496781 0.75 PTGER4 (0.49) JAK2DYRK1ANPSR1MEN1RAB9A
SCHEMBL20891566 0.72 TSHR (0.41) NPSR1KDM4EMAPTALOX15MEN1
SCHEMBL22860320 0.72 RIPK1 (0.47) SYKKDM4EALDH1A1
SCHEMBL3286253 0.72 MAPT (0.47) FERSYKMAPK1NPSR1KDM4E
SCHEMBL12936321 0.71 RIPK1 (0.49) SYKKDM4EALDH1A1
Hydrochloric Acid SCHEMBL3286250 0.71 MAPT (0.46) FERMAPK1NPSR1KDM4EMAPT
SCHEMBL495713 0.70 NR2F2 (0.53) MAPK1NR2F2NPSR1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1955697-B1 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER ASTELLAS PHARMA INC (JP) 2012-05-02 EP disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-8106190-B2 2-aminobenzamide derivatives ASTELLAS PHARMA INC. (JP) 2012-01-31 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2009-09-17 US disclosed
EP-1955697-A1 2-AMINOBENZAMIDE DERIVATIVE Astellas Pharma Inc. (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233900-A1 2-AMINOBENZAMIDE DERIVATIVE TRPV1, TRPV2, TRPV5 FER 4641/4885SYK 4381/4885MAPK1 1633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.